Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HEATHER D PUGMIRE

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1225292220
CMS profile
1251876
Location
BLACKFOOT, ID

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$191.39

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $173.95 10
Education $17.44 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Exeltis, USA Inc. $47.15 3
ABBVIE INC. $38.01 2
Ethicon US, LLC $30.74 1
PFIZER INC. $17.44 1
TherapeuticsMD, Inc. $16.78 1
Bayer HealthCare Pharmaceuticals Inc. $15.00 1
Hologic, LLC $13.77 1
Agile Therapeutics, Inc. $12.50 1

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HEATHER D PUGMIRE

NPI 1225292220 · CMS profile ID 1251876

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

BLACKFOOT, ID

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1225292220?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HEATHER D PUGMIRE, NPI 1225292220, CMS profile ID 1251876. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1225292220?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). HEATHER D PUGMIRE, NPI 1225292220, CMS profile ID 1251876. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1225292220?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
HEATHER D PUGMIRE, NPI 1225292220, CMS profile ID 1251876, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1225292220?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $191.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
TherapeuticsMD, Inc. $16.7808/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930762671 CMS
Exeltis, USA Inc. $19.9307/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951307121 CMS
Bayer HealthCare Pharmaceuticals Inc. $15.0007/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929791839 CMS
Ethicon US, LLC $30.7405/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887066171 CMS
Hologic, LLC $13.7705/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 877678561 CMS
PFIZER INC. $17.4404/27/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949427531 CMS
Agile Therapeutics, Inc. $12.5004/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957204751 CMS
Exeltis, USA Inc. $13.0804/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951324745 CMS
ABBVIE INC. $19.3403/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891395465 CMS
ABBVIE INC. $18.6703/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891395463 CMS
Exeltis, USA Inc. $14.1402/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951334387 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,156.29 10
PY2020 $168.45 10
PY2021 $54.17 4
PY2022 $191.39 11
PY2023 $121.34 6
PY2024 $154.37 5
PY2025 $27.23 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $47,335.41 30
PY2024 Principal investigator $1,715.25 5
PY2023 Principal investigator $563,369.78 70
PY2022 Principal investigator $1,001,804.43 53
PY2021 Principal investigator $615,914.73 46
PY2020 Principal investigator $234,310.20 35
PY2019 Principal investigator $142,548.53 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $2,955.55 12/10/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832536097
Principal investigator 1 PFIZER INC. $19,203.60 12/07/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832538887
Principal investigator 1 PFIZER INC. $81,073.98 11/23/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832915385
Principal investigator 1 PFIZER INC. $542.75 11/17/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832617377
Principal investigator 1 PFIZER INC. $28,662.40 11/05/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832890315
Principal investigator 1 PFIZER INC. $2,346.50 10/21/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832701803
Principal investigator 1 PFIZER INC. $1,416.35 10/19/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832618855
Principal investigator 1 PFIZER INC. $29,955.90 10/08/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832877329
Principal investigator 1 PFIZER INC. $2,098.85 09/29/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832616375
Principal investigator 1 PFIZER INC. $22,627.15 09/22/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832887569
Principal investigator 1 PFIZER INC. $2,587.00 09/21/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832619037
Principal investigator 1 PFIZER INC. $4,477.20 09/10/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832616365
Principal investigator 1 PFIZER INC. $27,360.45 09/04/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832772531
Principal investigator 1 PFIZER INC. $5,864.30 09/01/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832618865
Principal investigator 1 PFIZER INC. $1,114.75 08/25/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832619057
Principal investigator 1 PFIZER INC. $20,168.85 08/21/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832720423
Principal investigator 1 PFIZER INC. $72,337.85 08/06/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832856471
Principal investigator 1 PFIZER INC. $4,473.95 07/31/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832619245
Principal investigator 1 PFIZER INC. $711.75 07/24/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832618845
Principal investigator 1 PFIZER INC. $12,914.20 07/20/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832703237
Principal investigator 1 PFIZER INC. $2,203.50 07/17/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832618221
Principal investigator 1 PFIZER INC. $6,672.25 07/14/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832618230
Principal investigator 1 PFIZER INC. $2,229.50 06/30/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832619235
Principal investigator 1 PFIZER INC. $25,645.75 06/23/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832723761
Principal investigator 1 PFIZER INC. $4,750.20 06/16/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832617387
Principal investigator 1 PFIZER INC. $7,334.60 06/11/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832619255
Principal investigator 1 PFIZER INC. $36,099.05 05/21/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832898215
Principal investigator 1 ABBVIE INC. $8,174.10 05/06/2021 Non-covered Recipient Entity
BINGHAM MEMORIAL HOSPITAL
Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome No dispute reported 06/30/2026 792454603
Principal investigator 1 PFIZER INC. $30,875.00 04/24/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832871085
Principal investigator 1 PFIZER INC. $9,750.00 04/20/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832619047
Principal investigator 1 PFIZER INC. $10,618.40 04/09/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832816933
Principal investigator 1 PFIZER INC. $9,545.90 03/24/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832735643
Principal investigator 1 PFIZER INC. $3,074.50 03/24/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832877339
Principal investigator 1 PFIZER INC. $13,496.00 03/15/2021 Non-covered Recipient Entity
Bingham Memorial Hospital
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 948971953
Principal investigator 1 PFIZER INC. $9,321.00 03/13/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832890305
Principal investigator 1 ABBVIE INC. $1,890.20 03/08/2021 Non-covered Recipient Entity
BINGHAM MEMORIAL HOSPITAL
Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome No dispute reported 06/30/2026 792432385
Principal investigator 1 PFIZER INC. $10,509.20 03/05/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832859395
Principal investigator 1 PFIZER INC. $692.25 02/24/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832696907
Principal investigator 1 PFIZER INC. $30,741.10 02/23/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832753289
Principal investigator 1 PFIZER INC. $1,384.50 02/05/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832700527
Principal investigator 1 PFIZER INC. $578.50 02/05/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832728141
Principal investigator 1 ABBVIE INC. $4,178.20 02/04/2021 Non-covered Recipient Entity
BINGHAM MEMORIAL HOSPITAL
Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome No dispute reported 06/30/2026 792420579
Principal investigator 1 PFIZER INC. $14,781.00 01/16/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832692441
Principal investigator 1 PFIZER INC. $1,384.50 01/12/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832767081
Principal investigator 1 PFIZER INC. $21,860.80 01/09/2021 Non-covered Recipient Entity
BMH Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832891179
Principal investigator 1 ABBVIE INC. $5,231.40 01/05/2021 Non-covered Recipient Entity
BINGHAM MEMORIAL HOSPITAL
Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome No dispute reported 06/30/2026 792407168